z-logo
open-access-imgOpen Access
Prognostic significance of genetic polymorphisms on prostate-specific antigen recurrence after a radical prostatectomy
Author(s) -
Yueh-Fong Tsai,
Bo-Ying Bao,
Chia-Chu Liu,
ChingWen Huang,
ChiaCheng Yu,
Tony T. Wu,
ChaoYuan Huang,
Yeong-Shiau Pu,
ChiFon Chang,
ChunHsiung Huang,
WenJeng Wu,
ShuPin Huang
Publication year - 2012
Publication title -
urological science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.155
H-Index - 8
eISSN - 1879-5234
pISSN - 1879-5226
DOI - 10.1016/j.urols.2012.03.005
Subject(s) - prostatectomy , medicine , prostate cancer , biochemical recurrence , prostate specific antigen , single nucleotide polymorphism , oncology , surgical margin , urology , cancer , genotype , gene , biology , genetics
Approximately one-third of patients with prostate cancer show prostate-specific antigen (PSA) recurrence (biochemical failure) after a radical prostatectomy and are prone to developing metastasis with significant mortality. Although several clinicopathologic indicators, such as the PSA level, Gleason score, pathologic stage, and surgical-margin status, are used to predict outcomes after a curative-intended radical prostatectomy for localized prostate cancer, new biomarkers are still required to improve the prognosis and plan appropriate adjuvant therapy, particularly for patients at high risk of recurrence. DNA-based genetic biomarkers have several advantages over clinicopathologic indicators because they can be preoperatively examined, are easily evaluated, and can be interpreted more objectively without individual bias. In this study, the literature was reviewed from the PubMed database using the keywords “genetic polymorphisms” and “radical prostatectomy” from 1985 to April 2011. The results showed that genetic variants discovered from genome-wide association studies (such as rs1447295, rs1447295, rs6983561, rs13254738, Broad11934905, rs6983267, and rs7000448 at 8q24, rs7920517 and rs10993994 at 10q11, rs10486567 in the 7JAZF1, rs198977 in the KLK2, rs9282861 in the SULT1A1, and rs1536889 in the TLR4 gene) and single-nucleotide polymorphisms (SNPs) in important pathways (RUNX1, FGFR4, EGFR, VEGF, TNFRSF11B, vitamin D receptor, p53, WNT, inflammatory, androgen synthesis, and metabolism pathways) on prostate cancer occurrence and progression could serve as biomarkers to predict PSA recurrence after a radical prostatectomy. Including the genetic information might improve predictions of PSA recurrence after a radical prostatectomy. Future studies can be dedicated to confirming these findings in other ethnic cohorts and clarifying the roles of these SNPs/genes in the course of prostate cancer progression after a radical prostatectomy through functional analyses

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here